Table 3. RMST Analysis of HCC Incidence in Patients Treated With Tenofovir vs Entecavir Stratified by Clinical Cohort or Administrative Database Studies.
| Follow-up year | RMST (95% CI), y | RMST difference (95% CI), y | P value | RMST ratio (95% CI) | P value | |
|---|---|---|---|---|---|---|
| Tenofovir | Entecavir | |||||
| Clinical cohort | ||||||
| 1 | 0.997 (0.996 to 0.998) | 0.997 (0.996 to 0.998) | 0.000 (−0.002 to 0.002) | .99 | 1.000 (0.998 to 1.002) | .99 |
| 2 | 1.981 (1.978 to 1.985) | 1.980 (1.976 to 1.983) | 0.002 (−0.003 to 0.006) | .53 | 1.001 (0.999 to 1.003) | .53 |
| 3 | 2.945 (2.938 to 2.953) | 2.942 (2.935 to 2.949) | 0.003 (−0.007 to 0.014) | .53 | 1.001 (0.998 to 1.005) | .53 |
| 4 | 3.892 (3.879 to 3.904) | 3.882 (3.870 to 3.894) | 0.009 (−0.008 to 0.027) | .29 | 1.002 (0.998 to 1.007) | .29 |
| 5 | 4.823 (4.804 to 4.842) | 4.803 (4.785 to 4.821) | 0.020 (−0.006 to 0.046) | .13 | 1.004 (0.999 to 1.010) | .13 |
| Administrative studies | ||||||
| 1 | 0.995 (0.994 to 0.996) | 0.995 (0.994 to 0.996) | 0.000 (−0.001 to 0.001) | .99 | 1.000 (0.999 to 1.001) | .99 |
| 2 | 1.972 (1.969 to 1.975) | 1.969 (1.966 to 1.972) | 0.003 (−0.001 to 0.007) | .14 | 1.002 (0.999 to 1.004) | .14 |
| 3 | 2.937 (2.932 to 2.943) | 2.926 (2.920 to 2.931) | 0.011 (0.003 to 0.019) | .005 | 1.004 (1.001 to 1.007) | .005 |
| 4 | 3.899 (3.890 to 3.907) | 3.868 (3.860 to 3.877) | 0.030 (0.018 to 0.042) | <.001 | 1.008 (1.005 to 1.011) | <.001 |
| 5 | 4.864 (4.833 to 4.859) | 4.793 (4.781 to 4.806) | 0.053 (0.035 to 0.071) | <.001 | 1.011 (1.007 to 1.015) | <.001 |
Abbreviations: HCC, hepatocellular carcinoma; RMST, restricted mean survival time.